• Online Features  This Article  • Full text  • PDF  • eTables  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (50)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Critical Care/ Intensive Care Medicine  • Adult Critical Care  • Quality of Care  • Evidence-Based Medicine  • Review  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Systematic Review and Meta-analysis

Imad M. Tleyjeh, MD, MSc; Tarek Kashour, MD; Fayaz A. Hakim, MD; Valerie A. Zimmerman, PhD; Patricia J. Erwin, MLS; Alex J. Sutton, PhD; Talal Ibrahim, MBBS(Hons), MD, FRCS(Tr&Orth)

Arch Intern Med. 2009;169(18):1658-1667.

Background  Emerging epidemiological evidence suggests that statin use may reduce the risk of infections and infection-related complications. Our objective was to examine the association between statin use and the risk of infections and related outcomes.

Methods  We searched several electronic databases from inception through December 2007 for randomized trials and cohort studies that examined the association between statin use and the risk or outcome of infections. Data on study characteristics, measurement of statin use, outcomes (adjusted for potential confounders), and quality assessment were extracted.

Results  Sixteen cohorts were eligible and differed in representativeness, outcome assessment, and comparability of exposed (statin) and unexposed (nonstatin) groups. Nine cohorts addressed the role of statins in treating infections: bacteremia (n = 3), pneumonia (n = 3), sepsis (n = 2), and bacterial infection (n = 1). The pooled adjusted effect estimate was 0.55 (95% confidence interval, 0.36-0.83; I² = 76.5%) in favor of statins. Seven cohorts addressed infection prevention in patients with vascular diseases (n = 3), chronic kidney disease (n = 1), diabetes (n = 1), intensive care unit–acquired infections (n = 1), and in general practice (n = 1). The pooled effect estimate was 0.57 (95% confidence interval, 0.43-0.75; I² = 82%) in favor of statin use; there was some evidence of publication bias for this analysis (Egger test; P = .07). Meta-regression did not identify potential effect modifiers that explain the between-study heterogeneity.

Conclusions  Results for our meta-analysis suggest that statin use may be associated with a beneficial effect in treating and preventing different infections. Given the presence of heterogeneity and publication bias, there is a need for randomized trials to confirm the benefit of statin use in this context.

Author Affiliations: Division of Infectious Diseases, Department of Medicine (Dr Tleyjeh), Research Center (Drs Tleyjeh and Zimmerman), and Cardiac Center (Dr Kashour), King Fahd Medical City, Riyadh, Saudi Arabia; Department of Medicine (Drs Tleyjeh and Hakim), Mayo Medical Library (Ms Erwin), Mayo Clinic, Rochester, Minnesota; Section of Cardiology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada (Dr Kashour); and Division of Orthopedic Surgery (Dr Ibrahim), Department of Health Sciences (Dr Sutton), University of Leicester, Leicester, England.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Farnesyltransferase Inhibitor FTI-277 Reduces Mortality of Septic Mice along with Improved Bacterial Clearance
Yang et al.
J. Pharmacol. Exp. Ther. 2011;339:832-841.
ABSTRACT | FULL TEXT  

Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials
van den Hoek et al.
BMJ 2011;343:d7281-d7281.
ABSTRACT | FULL TEXT  

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK
Sever et al.
Eur Heart J 2011;32:2525-2532.
ABSTRACT | FULL TEXT  

Opportunistic Infection-Associated Immune Reconstitution Syndrome in Transplant Recipients
Sun and Singh
Clinical Infectious Diseases 2011;53:168-176.
ABSTRACT | FULL TEXT  

Effect of statin treatment on short term mortality after pneumonia episode: cohort study
Douglas et al.
BMJ 2011;342:d1642-d1642.
ABSTRACT | FULL TEXT  

Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study
Humes et al.
Gut 2011;60:219-224.
ABSTRACT | FULL TEXT  

Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice
Miller et al.
J Gerontol A Biol Sci Med Sci 2011;66A:191-201.
ABSTRACT | FULL TEXT  

Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study
Milazzo et al.
J Antimicrob Chemother 2010;65:735-740.
ABSTRACT | FULL TEXT